Like breast cancer in women, prostate cancer is a major public health concern in American men. One of the major roadblocks to improving the outcome of this disease is a current lack of understanding of how to accurately determine the risk of disease progression. Without this information, it is difficult to make an informed decisions about what type of treatment is most appropriate, or whether any treatment is needed at all. Although there are many studies in the prostate cancer literature evaluating the diagnostic accuracy of imaging for pretreatment staging using standard pathologic endpoints, there is little data on the ability of imaging to predict tumor aggressiveness or patient outcomes. The broad, long-term objective of this proposed research is to improve the treatment of patients with prostate cancer by the judicious use of diagnostic imaging tests to accurately stage the disease and to help determine the risk of disease progression. Our proposed research investigates a possible new tumor risk factor, which may be used in conjunction with existing risk factors to provide a more accurate assessment of tumor aggressiveness than is currently possible. We wish to test the hypothesis that the morphologic (MRI) and metabolic (MRSI) information provided by MR imaging allows more accurate determination of tumor aggressiveness and prediction of patient outcome than the use of clinical risk factors alone.
The specific aims of our study are to: 1. Determine whether the severity of abnormality in metabolism in areas of prostate cancer identified by MRSI represents a significant new independent measure of tumor aggressiveness. 2. Compare the accuracy of MRSI, MRI, and TRUS in determining the local extent of tumor in patients who will undergo radical prostatectomy. 3. Determine the best way to combine the diagnostic information obtained from MRSI, MRI, TRUS, and clinical risk factors to provide more accurate risk assessment than the use of any diagnostic test alone.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA076423-05
Application #
6633294
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Menkens, Anne E
Project Start
1999-07-07
Project End
2005-04-30
Budget Start
2003-08-01
Budget End
2005-04-30
Support Year
5
Fiscal Year
2003
Total Cost
$220,709
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Shukla-Dave, Amita; Castillo-Martin, Mireia; Chen, Ming et al. (2016) Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. Am J Pathol 186:3131-3145
Zakian, Kristen L; Hatfield, William; Aras, Omer et al. (2016) Prostate MRSI predicts outcome in radical prostatectomy patients. Magn Reson Imaging 34:674-81
Matulewicz, Lukasz; Jansen, Jacobus F A; Bokacheva, Louisa et al. (2014) Anatomic segmentation improves prostate cancer detection with artificial neural networks analysis of 1H magnetic resonance spectroscopic imaging. J Magn Reson Imaging 40:1414-21
Mazaheri, Yousef; Vargas, H Alberto; Nyman, Gregory et al. (2013) Image artifacts on prostate diffusion-weighted magnetic resonance imaging: trade-offs at 1.5 Tesla and 3.0 Tesla. Acad Radiol 20:1041-7
Barrett, Tristan; Vargas, Hebert Alberto; Akin, Oguz et al. (2012) Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology 263:751-7
Vargas, Hebert Alberto; Akin, Oguz; Franiel, Tobias et al. (2012) Normal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications. Radiology 262:894-902
Mazaheri, Yousef; Vargas, Hebert Alberto; Akin, Oguz et al. (2012) Reducing the influence of b-value selection on diffusion-weighted imaging of the prostate: evaluation of a revised monoexponential model within a clinical setting. J Magn Reson Imaging 35:660-8
Wassberg, Cecilia; Akin, Oguz; Vargas, Hebert Alberto et al. (2012) The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR Am J Roentgenol 199:360-6
Vargas, Hebert Alberto; Akin, Oguz; Afaq, Asim et al. (2012) Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol 188:1732-8
Shukla-Dave, Amita; Hricak, Hedvig; Akin, Oguz et al. (2012) Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int 109:1315-22

Showing the most recent 10 out of 48 publications